Should patients with persistent severe asthma be monitored for medication adherence?

Annals of Allergy, Asthma and Immunology

Volumn 94, Issue 2, 2005, Pages 251-257

  Weinstein, Andrew G ^a,b  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b 310 Christiana Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIETY; ASTHMA; COST CONTROL; DEPRESSION; DRUG MONITORING; ETHICS; HEALTH CARE COST; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; METERED DOSE INHALER; MONITOR; MORBIDITY; PATIENT COMPLIANCE; PHARMACY; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 13944283250     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61304-X     Document Type: Article

References (61)

1. Centers for Disease Control and Prevention. Asthma Prevalence, Health Care Use and Mortality, 2000-2001. Hyattsville, MD: National Center for Health Statistics, US Dept of Health and Human Services; 2001.
2. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis, I: assessing the economic impact. J Allergy Clin Immunol. 2001;107:3-8.
3. Moore B, Sullivan S, Weiss K. Epidemiology and socioeconomic impact of severe asthma. In: Szefler S, Leung D, eds. Severe Asthma: Pathogenesis and Clinical Management. New York, NY: Marcel Dekker; 1996:1-34.
4. Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 2003;111:1212-1218.
5. Glaxo Canada. The Costs of Adult Asthma in Canada. Princeton, NJ: Communications Media for Education; 1993.
6. National Asthma Campaign. Report on the Cost of Asthma in Australia. South Melbourne: National Asthma Council Australia; 1992.
7. Baker KM, Brand DA, Hen J. Classifying asthma: disagreement among specialists. Chest. 2002;124:2156-2163.
8. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57:880-884.
9. Sackett DL, Haynes RB. Introduction. In: Compliance With Therapeutic Regimens. Baltimore, MD: Johns Hopkins University Press; 1976:1.
10. Rand C, Wise RA. Measuring adherence to asthma therapy. Am J Respir Crit Care Med. 1004;149:S69-S76.
11. Spector SL, Kinsman R, Mawhinney H, et al. Compliance of patients with asthma with an experimental aerosolized medication: implications for controlled clinical trials. J Allergy Clin Immunol. 1986;77:65-70.
12. Mawhinney H, Spector SL, Heitjan D, et al. As-needed medication use in asthma usage patterns and patient characteristics. J Asthma. 1993;30:61-71.
13. Coutts JAP, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child. 1992;67:332-333.
14. Gibson AE, Aitchison TC, Paton JY. Compliance with inhaled asthma medication in preschool children. Thorax. 1995;50:1274-1279.
15. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004;113:245-251.
16. Milgrom H, Bender B, Ackerson L, et al. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol. 1996;98:1051-1057.
17. Mann MC, Eliasson O, Patel K, ZuWallack RL. An evaluation of severity-modulated compliance with q.i.d. dosing of inhaled beclomethasone. Chest. 1992;102:1342-1346.
18. Jonasson G, Carlsen KH, Sodal A, et al. Patient compliance in a clinical trial with inhaled budesonide in children with mild asthma. Eur Respir J. 1999;14:150-154.
19. Sherman J, Hutson A, Baumstein S, Hendeles L. Telephoning the patient's pharmacy to assess adherence with asthma medications by measuring refill rate for prescriptions. J Pediatr. 2000;136:532-536.
20. Rand C. I took the medicine like you told me, doctor: self-report of adherence with medical regimens. In: Stone AA, Turkkan JS, Bachrach CA, et al, eds. The Science of Self-Report. Mahwah, NJ: Lawrence Erlbaum Associates; 1999:257-276.
21. Weinstein AG, Feldstein J, Esterly K. Final report regarding asthma adherence. Del Med J. 2001;73:341-345.
22. Korsch BM, Negrete VF. Doctor-patient communication. Sci Am. 1972;227:66-74.
23. National Institutes of Health, National Heart, Lung, and Blood Institute. Practical Guide for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute; 1997. NIH publication 97-4053.
24. Jarjour N, McGill K, Busse WW, Gelfand EW. Alternative anti-inflammatory and immunomodulatory therapy. In: Szeffler SJ, Leung DYM, eds. Severe Asthma: Pathogenesis and Clinical Management. New York, NY: Marcel Dekker; 1996: 333-369.
25. Barnes PJ. Anti-IgE antibody therapy for asthma. N Engl J Med. 1999;341:2006-2008.
26. Spector SL. Treatment of the unusually difficult asthmatic patient. Allergy Asthma Proc. 1997;18:153-155.
27. Haynes RB. Determinants of compliance: the disease and the mechanics of treatment. In: Haynes RB, Taylor DW, Sackett D, eds. Compliance in Healthcare. Baltimore, MD: Johns Hopkins University Press; 1987:59-60.
28. Jonasson G, Carlsen K, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child. 2000;83:330-331.
29. Vamos M, Kolbe J. Psychological factors in severe chronic asthma. Aust NZJ Psychiatry. 1999;33:538-544.
30. Cuffel B. Economic consequences of comorbid depression, anxiety, and allergic rhinitis. Psychosomatics. 1999;40:491-496.
31. Mrazek D. Asthma: psychiatric considerations, evaluation, and management. In: Middleton E, et al, eds. Allergy Principles and Practice. Washington, DC: Mosby; 1988:1176-1196.
32. Strunk RC. Physiologic and psychological characteristics associated with deaths due to asthma in childhood. JAMA. 1985;254:1193-1198.
33. Fritz GK, Overholser JC. Patterns of response to childhood asthma. Psychosom Med. 1989;51:347-355.
34. Christiaanse ME, Lavigne JV, Lerner CV. Psychosocial aspects of compliance in children and adolescents with asthma. J Dev Behav Pediatr. 1989;10:75-80.
35. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med. 2000;160:2101-2107.
36. Tran MHM. Quality of Life and Economic Burden of Chronic Oral Steroid-Dependent Asthmatics. Research Triangle Park, NC: Glaxo Research Institute; 1994. Publication No. UPE/94/022.
37. Yeung M, O'Connor SA, Parry DT, Cochrane GM. Compliance with prescribed drug therapy in asthma. Respir Med. 1994;88:31-35.
38. Onyirimba F, Apter A, Reisine S, et al. Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherence. Ann Allergy. 2003;90:411-415.
39. Nides MA, Tashkin DP, Simmons MS, et al. Improving inhaler adherence in a clinical trial through the use of the nebulizer. Chest. 1993;104:501-507.
40. Eney RD, Goldstein EO. Compliance of chronic asthmatics with oral administration of theophylline as measured by serum and salivary levels. Pediatrics. 1976;57:513-517.
41. Matsuymara JR, Manson BJ, Jue SC. Pharmacists' interventions using an electronic medication-event monitoring device's adherence data versus pill count. Ann Pharmacother. 1993;27:851-855.
42. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA. 2002;288:2868-2879.
43. Bender B, Milgrom H, Apter A. Adherence intervention research: what have we learned and what do we do next. J Allergy Clin Immunol. 2003;112:489-494.
44. Bartlett SL, Lukk P, Butz A, et al. Enhancing medication adherence among inner-city children with asthma: results from pilot studies. J Asthma. 2002;39:47-54.
45. Weinstein AG, Faust DS, McKee L, Padman R. Outcome of short-term hospitalization for children. J Allergy Clin Immunol. 1992;90:66-75.
46. Weinstein AG, Chenkin C, Faust D. Caring for the severely asthmatic child and family: a family-focused inpatient psychoeducational approach: a case report. Families Syst Health. 1997;15:175-183.
47. Weinstein AG, McKee L, Stapleford J, Faust D. An economic evaluation of short-term inpatient rehabilitation for severe asthmatic children. J Allergy Clin Immunol. 1996;98:264-273.
48. Tashkin D. Microelectronics adherence monitors for metered-dose inhalers: who monitors the monitors? J Allergy Clin Immunol. 1999;104:22-23.
49. Apter AJ, Meltem T, Feldman HJ. Testing the reliability of old and new features of a new electronic meter for metered-dose inhalers. Ann Allergy Asthma Immunol. 2001;86:421-424.
50. Weeks K, Schweiger D, Wise R, Rand C. Accuracy of the MDILog: a new electronic metered-dose inhaler monitor. Ann Behav Med. 1998;20:S223-S224.
51. Julius SM, Sherman JM, Hendeles L. Accuracy of electronic monitors for metered-dose inhalers. Chest. 2002;121:871-876.
52. Lynd LD, Guh DP, Pare PD, Anis AH. Patterns of inhaled asthma medication use: a 3-year longitudinal analysis of prescription claims data from British Columbia, Canada. Chest. 2002;122:1973-1981.
53. Skaer T, Sclar D, Markowski D, Won J. Effect of value-added utilities on prescription refill compliance and Medicaid health care expenditures: a study of patients with non-insulin-dependent diabetes mellitus. J Clin Pharm Ther. 1993;18:295-299.
54. Sahney V, Warden GL. The quest for quality and productivity in health services. Front Health Serv Manage. 1991;7:2-40.
55. Weinstein AG. Asthma treatment and non-compliance. Del Med J. 2000;72:209-213.
56. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2002.
57. Bender B, Boulet LP, Chaustre I, Rand C, Weinstein A. Asthma. In: Sabate E, ed. Adherence to Long-term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003:56.
58. Bengoa R, Yach D, De Castro S. Towards the solution. In: Sabate E, ed. Adherence to Long-term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003: 27.
59. Current Procedural Terminology: CPT 2004. Chicago, Ill: American Medical Association; 2003.
60. Rand CS, Sevick A. Ethics in adherence promotion and monitoring. Control Clin Trials. 2000;21:241S-247S.
61. Hess JD. The ethics of compliance. Adv Nurs Sci. 1996;19:18-27